For the quarter ending 2026-03-31, SNDX has $472,668K in assets. $431,046K in debts. $130,893K in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 130,893 | 134,930 | 116,808 | 108,636 |
| Short-term investments | 221,171 | 259,140 | 319,171 | 346,597 |
| Accounts receivable, net | 38,116 | 37,996 | 25,403 | 19,454 |
| Inventory, net | - | 32,754 | - | - |
| Inventory | 34,948 | - | 25,000 | 17,696 |
| Short-term deposits | 9,175 | 19,616 | 18,195 | 13,473 |
| Other receivable, net | 267 | 6,404 | 0 | 3,629 |
| Collaboration receivable, net | 20,507 | 23,745 | 15,736 | 12,316 |
| Prepaid expenses and other current assets | 16,100 | 13,496 | 9,517 | 9,875 |
| Total current assets | 471,177 | 528,081 | 529,830 | 531,676 |
| Long-term investments | - | 0 | 20,146 | 62,627 |
| Property and equipment, gross | 606 | 606 | - | - |
| Accumulated depreciation | 429 | 425 | - | - |
| Property and equipment, net | 177 | 181 | 128 | 0 |
| Right-of-use asset, net | 1,212 | 1,342 | 1,471 | 1,629 |
| Restricted cash | 102 | 102 | 217 | 217 |
| Total assets | 472,668 | 529,706 | 551,792 | 596,149 |
| Accounts payable | 10,843 | 16,580 | 13,826 | 17,353 |
| Collaboration payable, net | - | 0 | 0 | 0 |
| Royalty payable | - | - | - | 4,783 |
| Accrued expenses and other current liabilities | 74,843 | 103,064 | 77,105 | 71,066 |
| Current portion of royalty interest financing liability | - | - | 22,925 | 19,435 |
| Current portion of royalty interest financing | - | 0 | - | - |
| Current portion of right-of-use liability | 487 | 470 | 329 | 344 |
| Current portion of capital lease | 1 | 2 | 2 | 6 |
| Total current liabilities | 86,174 | 120,116 | 114,187 | 112,987 |
| Royalty interest financing, less current portion | - | 343,909 | - | - |
| Royalty interest financing liability, less current portion | 343,965 | - | 320,985 | 324,413 |
| Right-of-use liability, less current portion | 907 | 1,051 | 1,190 | 1,325 |
| Total long-term liabilities | 344,872 | 344,960 | 322,175 | 325,738 |
| Total liabilities | 431,046 | 465,076 | 436,362 | 438,725 |
| Common stock, 0.0001 par value, 200,000,000 shares authorized 86,905,343 and 85,694,443 shares issued and outstanding at september 30, 2025 and december 31, 2024, respectively | 9 | 9 | 9 | 9 |
| Additional paid-in capital | 1,590,855 | 1,570,749 | 1,553,462 | 1,534,981 |
| Accumulated other comprehensive gain | 11 | 452 | 525 | 285 |
| Accumulated deficit | -1,549,253 | -1,506,580 | -1,438,566 | -1,377,851 |
| Total stockholders equity | 41,622 | 64,630 | 115,430 | 157,424 |
| Total liabilities and stockholders equity | 472,668 | 529,706 | 551,792 | 596,149 |
Syndax Pharmaceuticals Inc (SNDX)
Syndax Pharmaceuticals Inc (SNDX)